Tag: registration

NEW YORK, July 23, 2026 (GLOBE NEWSWIRE) -- Pelican Acquisition II Corporation (NASDAQ: PLCIU) (the “Company”), a Cayman Islands exempted company, announced that it priced its initial public offering of 7,500,000 units at $10.00 per unit on July 23, 2026. The units will be listed on the Nasdaq Capital Market (“NASDAQ”) and are expected to trade under the ticker symbol “PLCIU” beginning on July 24, 2026. Each unit consists of one ordinary share of the Company and one right, with each right entitling the holder thereof to receive one-tenth (1/10) of one ordinary share upon the consummation of an initial business combination.  

BEVERLY, Mass., July 23, 2026 (GLOBE NEWSWIRE) -- ATN International, Inc. (“ATN” or the “Company”) (Nasdaq: ATNI), a provider of digital infrastructure and communications services, announced today that it will release its second quarter 2026 financial results on Wednesday, August 5, 2026, after market close. The Company will host a conference call to discuss the results starting at 11:00 a.m. Eastern time on Thursday, August 6, 2026.

ST. JOHN'S, Newfoundland and Labrador, July 23, 2026 (GLOBE NEWSWIRE) --

Fortis Inc. ("Fortis" or the "Corporation") (TSX/NYSE: FTS) will release its second quarter 2026 financial results on Friday, July 31, 2026. A teleconference and webcast will be held the same day at 8:30 a.m. (Eastern). David Hutchens, President and Chief Executive Officer and Jocelyn Perry, Executive Vice President and Chief Financial Officer will discuss the Corporation's second quarter financial results.

CALGARY, Alberta, July 22, 2026 (GLOBE NEWSWIRE) -- Cenovus Energy Inc. (TSX:CVE) (NYSE:CVE) will release its second-quarter 2026 results on Wednesday, July 29, 2026. The news release will provide consolidated second-quarter operating and financial information. The company’s financial statements will be available on Cenovus’s website, cenovus.com.

ROCKVILLE, Md., July 22, 2026 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that it will report second quarter 2026 financial and business results after the market closes on Tuesday, August 4, 2026.

Registration Statement was filed pursuant to a pre-existing contractual obligation to register securities issued in a previously disclosed private placement